Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review
Nutrition in Clinical Practice · 2025
DOI: 10.1002/ncp.11279 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrition in Clinical Practice, 2025. Verfasst von Jason Zupec und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Philadelphia College of Pharmacy at Saint Joseph's University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Incretins, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 100 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Incretin mimetics, including glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide agonists, have become first‐line treatment options for the treatment of type 2 diabetes and obesity. Their therapeutic status is attributed to their high level of efficacy as well as positive impact on related comorbidities, such as sleep apnea and heart failure. Multiple incretin mimetics are currently available with different durations of drug action, dosing frequencies, and delivery devices. Patients may benefit from education on the proper drug administration, anticipated adverse effects, and nutrition considerations with treatment. Practitioners must monitor progress and support the patient to achieve maintenance doses for optimal weight reduction and diabetes‐related outcomes. This review aims to present the current literature supporting US Food and Drug Administration–approved indications of incretin mimetics, equip healthcare professionals to optimize care for patients who are prescribed these agents, and provide insights into potential future applications, which may include dual‐ or triple‐mechanism agents that are injected or administered orally. Additional studies are anticipated with existing and future incretin mimetics for the treatment of type 2 diabetes, obesity, and related comorbidities in a rapidly developing therapeutic pipeline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Philadelphia College of Pharmacy at Saint Joseph's University, Philadelphia, Pennsylvania, USA.
Zitieren
APA
Zupec, J., Munger, R., Scaletta, A., & Quinn, D. H. (2025). Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review. Nutrition in Clinical Practice. https://doi.org/10.1002/ncp.11279
Vancouver
Zupec J, Munger R, Scaletta A, Quinn DH. Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review. Nutrition in Clinical Practice. 2025. doi:10.1002/ncp.11279
BibTeX
@article{Zupec2025,
author = {Zupec, Jason and Munger, Rebecca and Scaletta, Alice and Quinn, Diane H},
title = {Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review},
journal = {Nutrition in Clinical Practice},
year = {2025},
doi = {10.1002/ncp.11279}
}
EUVIMED